The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

Pirtobrutinib (brand name Jaypirca) could reduce progression or death risk by 46% in patients with chronic lymphocytic ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Immediate gastrectomy was performed due to perforation. Histopathological examination diagnosed a triple-expressor gastric Diffuse Large B-Cell Lymphoma (DLBCL) [Bcl-2 focal (60%), Bcl-6 focal (40%), ...

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...